为c-ros瘤基因1 (ROS1) 发现一流的蛋白质降解剂
Jiawen Yang1, Yifan Wu2, Qiaoliang Zhu3
1Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China; Shanghai Clinical Research and Trial Center, Shanghai 201210, China.
Bioorganic chemistry
|July 2, 2024
概括
研究人员开发了SIAIS039,这是第一个PROteolysis-TTargeting Chimera (PROTAC) 来降解ROS1融合基蛋白. 这种新的方法在非小细胞肺癌 (NSCLC) 模型中显示出优异的抗瘤作用,为患者提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- ROS1融合是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 目前的治疗方法可以抑制ROS1的活性,但不能消除致癌驱动因素.
- 蛋白质降解剂通过消除标蛋白质提供了更强大的治疗策略.
研究的目的:
- 开发和描述第一个ROS1特定的PROteolysis-TTargeting Chimera (PROTAC) 的特征.
- 评估新型PROTAC对ROS1融合驱动NSCLC的抗瘤疗效.
- 为了研究PROTAC的作用机制和药理动力学特征.
主要方法:
- 使用分子对接和合理药物设计的 PROTAC 设计.
- 在工程细胞系 (Ba/F3,HCC78) 进行表达ROS1融合的体外研究.
- 在活体中使用老鼠异种移植模型进行疗效评估.
- 涉及无处不在和蛋白质体降解途径的机制研究.
主要成果:
- SIAIS039有效地降解了多个ROS1融合基蛋白 (CD74-ROS1,SDC4-ROS1,SLC34A2-ROS1).
- SIAIS039表现出显著的抗瘤活性,抑制增殖,诱导细胞循环停止和亡.
- 与已批准的药物相比,PROTAC具有更高的疗效,并且与顶级抑制剂相匹配,具有良好的口服生物可用性.
结论:
- 通过向蛋白质降解,SIAIS039代表了针对ROS1融合阳性NSCLC的新且强效的治疗策略.
- 这项研究证实PROTAC技术是治疗由特定上蛋白驱动的癌症的有希望的方法.
- 这项工作为开发用于ROS1驱动恶性瘤的下一代PROTAC奠定了基础.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Rous Sarcoma Virus (RSV) and Cancer
5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.0K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
The Proteasome
8.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.6K


